Microbot Medical (NASDAQ: MBOT) CMO granted 105,000 stock options under equity plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Diaz-Cartelle Juan reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chief Medical Officer Juan Diaz-Cartelle received a grant of stock options covering 105,000 shares of common stock. These options were awarded at no cost as part of his compensation.
Under the company’s 2020 Omnibus Performance Award Plan, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan terms.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Diaz-Cartelle Juan
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 105,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 105,000 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Microbot Medical (MBOT) report on this Form 4?
Microbot Medical reported that Chief Medical Officer Juan Diaz-Cartelle received a grant of stock options for 105,000 shares. The options were awarded at no cost under the company’s 2020 Omnibus Performance Award Plan, reflecting equity-based executive compensation.
How many stock options did MBOT’s Chief Medical Officer receive?
MBOT’s Chief Medical Officer received stock options covering 105,000 shares of common stock. This entire amount was reported as held after the transaction, indicating a new grant rather than a sale or purchase of existing shares in the open market.
What is the vesting schedule for the 105,000 stock options at Microbot Medical?
The options vest in stages. On August 18, 2026, 25% of the 105,000-share grant becomes exercisable. The remaining 75% then vests in equal quarterly installments over the next 30 months, following the company’s 2020 Omnibus Performance Award Plan terms.
Are the newly granted MBOT stock options immediately exercisable by the CMO?
No, the stock options are not fully exercisable immediately. Only 25% will vest and become exercisable on August 18, 2026, and the remaining 75% will vest quarterly over 30 months, with vesting subject to potential acceleration or forfeiture under plan rules.
Under which plan were the 105,000 MBOT stock options granted?
The options were granted under Microbot Medical’s 2020 Omnibus Performance Award Plan, as amended. This plan governs vesting, exercisability, and conditions such as potential acceleration or forfeiture, making it the framework for the Chief Medical Officer’s equity compensation.